26.03.2024 - Law Offices of Howard G. Smith reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) .
02.01.2024 - Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE) of Rett Syndrome Patients under Compassionate Use Authorization NEW YORK, Jan. 02, 2024 (GLOBE . Seite 1
20.12.2023 - Significant activation of key developmental and metabolic gene pathways and potential compensatory mechanism with ANAVEX2-73 in Rett syndrome patientsNEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) - Anavex Life Sciences Corp. (“Anavex” or the “Company”) . Seite 1
24.11.2023 - Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ETNEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing .
25.10.2023 - ANAVEX3-71 treatment prevents cognitive impairment, reduces amyloid, and neuroinflammation even after a long drug washout ANAVEX3-71 halts neurodegeneration and prevents cognitive decline in a transgenic Alzheimer’s disease model . Seite 1